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INTRODUCTION
Incidence  of  bacterial  infection  from  Hospitals  accounts  for  
5-10% in most developed nations while in India one in four patients 
admitted  into  hospitals  acquire  bacterial  infection59.  Around  30% of 
patients in Intensive Care Units were contracting infections during their 
stay in hospital3, which leads to many complications in them.    
                Since 1940, Penicillin- the first beta lactam antibiotic  
remained  the  antibiotic  of  choice  for  many  years.  Bacteria  were  so 
inventive that they developed many mechanisms to escape the action of 
antibiotics  and  became  resistant.  Main  mechanism  was  by  the 
production of   β-lactamases. The first plasmid mediated β-lactamase 
was TEM – 1 which was described in 1960s. Antibiotic resistance was 
high among organisms isolated from Intensive Care Units3. 
              Over the last 25 years, many new β-lactam antibiotics have  
been developed, that  were specifically designed to be resistant to the 
hydrolytic  action  of  β-lactamases.  However  with  each  new  class  of 
antibiotic used to treat patients, because of inappropriate and extensive 
use new β-lactamases emerged that caused resistance to that particular 
group  of  drug.  This  was  due  to  the  continuous  mutation  of  the 
enzymes.22 Major effort to overcome this lead to introduction of the new 
class  of  β-lactam antibiotics,  the  third  generation  cephalosporin  like 
Cefotaxime,  which  became  widely  used  for  the  treatment  of  serious 
infection  due  to  gram  negative  bacilli,  in  1980s.49 Because  of  their 
expanded spectrum of action against bacteria, they were also called as 
Expanded  Spectrum  Antibiotics.  Due  to  extensive  use  of  third 
generation antibiotics, bacteria soon developed resistance, by means of a 
new  β-  lactamase.  Because  of  their  increased  spectrum  of  activity 
against  most  of  the  β-lactam  antibiotics  including  third  generation 
cephalosporins,  these  enzymes  were  called  Extended  Spectrum  Beta 
Lactamases (ESBL). 
First ESBL was identified in Klebsiella pneumoniae in Germany 
in 1983, 49 it was found to be a derivative of SHV type Beta Lactamase. 
They were encoded by transferable plasmids and hence dissemination of 
resistance to other members of gram negative bacilli occurred.
Major factor contributing to the production of ESBL is prolonged 
stay in Intensive Care Units.38
The  incidence  and  type  of  ESBL  vary  with  geographical 
locations.22                                           
Though Extended spectrum beta lactamases are responsible for 
nosocomial  outbreaks  of  infections  like  urinary  tract  infections, 
pneumonia, septicemia etc, the real incidence and prevalence of ESBL 
producing  bacteria  at  most  hospitals  remain  unknown.15 Failure  to 
control  outbreaks has  resulted in  the  appearance of new mutant  type 
Extended spectrum beta lactamase in the same institution and the same 
patient source. 
The  appearance  of  eight  different  Extended  Spectrum  Beta 
Lactamases (TEM-3, TEM-5, CAZ-2, CAI-3, CAI-6, CAI-7, SHV-4 and 
SHV-5) at Clermont-Ferrand hospital, since the first one in 1984 is a 
classic example.37 
Hence the present study was undertaken to study the Extended 
Spectrum Beta Lactamase producing gram negative bacilli isolated from 
Intensive Care Units of Government Stanley Hospital, Chennai. 
REVIEW OF LITERATURE
HISTORY: 
Antibiotic era started with discovery of penicillin by Alexander 
Flemming in 1928.23 Use of Penicillin started in 1941.  Emergence of 
resistance to β-lactam antibiotic began even before the introduction of 
penicillin.18   First β-Lactamase was found in E-coli prior to introduction 
of  penicillin.  Next  is  the  emergence  of  penicillin  resistance  in 
staphylococcus aureus due to plasmid encoded β-lactamase.
First plasmid mediated β-lactamase in gram negative organisms- 
TEM-1 was described in early 1960’s. It was first isolated in Escherichia 
coli from a patient Temoniera in Greece. It spread to other genera soon.
Another  common  plasmid  mediated  β-lactamase  found  in 
Klebsiella  pneumoniae  and  Escherichia  coli  are  SHV-1  (for  Sulph 
Hydryl Variable).
Over the last 20 years many new β-lactam antibiotics have been 
developed which were resistant to hydrolytic action of β-lactamases but 
because of over usage, these antibiotics also became resistant.
To overcome it, around 1980 3rd generation cephalosporins, also 
called broad spectrum cephalosporins were introduced. They were very 
resistant  to  already  existing  β-lactamases.  Because  of  their  extensive 
use,  they  also  became  resistant.  In  1983  in  Germany,  isolates  of 
Klebsiella  pneumoniae  and  other  enterobacteriaceae  were  found  to 
produce a plasmid-determined β-lactamase that hydrolyzed cefotaxime, 
as  well  as  other  newer  cephalosporins.  This  new β-lactamase,  called 
SHV-2  was  derived  from  a  mutation  in  the  well-known  SHV-1 
β-lactamase  commonly  found  in  Klebsiella,37 since  they  lead  to 
resistance of extended spectrum cephalosporins they are called extended 
spectrum β-lactamases.
β- Lactam antibiotics: 23 
They are antibiotics having a β-lactam ring. It comprises of 
1) Penicillins
2) Cephalosporins
3) Monobactams
4) Carbapenems
 All the β-lactam antibiotics have β-lactam ring in common which 
is made of 3 carbon atoms and one nitrogen atom. The other rings vary 
in respect of each group of antibiotics.
Penicillins:
The structure of Penicillin is 
1. β-lactam ring
2. Thiazolidone ring
3. site where β-lactamase will act
Types of Penicillins
I. Natural Penicillins  eg., Penicillin G
II. Semi synthetic Penicillins   
1. Acid resistant Penicillins eg., Penicillin V
2. Penicillinase resistant Penicillins eg., Methicillin, Oxacillin, 
Cloxacillin
3. Extended spectrum Penicillins. 
a. Amino penicillins eg., Ampicillin, Amoxycillin
b. Carboxy penicillins e.g., Carbenicillin
c. Ureido penicillins  e.g., Piperacillin, mezlocillin
Cephalosporins: 
Have β- lactam ring attached to dihyro thiazine ring. By addition of 
different side chains to dihyro thiazine ring a large number of semi 
synthetic compounds have been produced. They are divided into four 
generations 
I – Generation: Cephalothin, Cephalexin, Cefadroxil, Cefazolin.
II – Generation: Cefuroxime, Cefuroxime Axetil, Cefaclor, Cefoxitin.
III – Generation: Cefotaxim, Ceftazidime, Cefixim, Cefoperazone.
IV – Generation: Cefepime, Cefpirome.
Monobactams: 
Monobactams have a monocyclic β-lactam ring and are 
resistant to β-lactamase. They are active against gram negative 
bacteria but not against gram positive bacteria. e.g., Aztreonam.
Carbapenems: 
These drugs are structurally related to the β-lactam antibiotics. They are 
extremely potent and have very broad spectrum of activity. e.g., Imipenem, 
Carbapenem. They are indicated in infections due to organisms resistant to 
other drugs.28 
Mechanism of Action of  β-lactam antibiotics  :  
β-lactam  antibiotics  act  by  inhibiting  cell  wall  synthesis  of 
bacteria.
Bacteria synthesise UDP – N – Acetyl muramic acid pentapeptide 
and UDP – N – Acetyl glucosamine. Peptidoglycan residues are linked 
together and UDP is split off. Final step is cleavage of the terminal   
D-alanine of the peptide chains by Tran’s peptidases and cross linking 
between  peptide  chains  of  the  neighbouring  strands.   β-lactam 
antibiotics inhibits trans peptidases so that cross linking is not formed.23 
Mechanism of resistance to β-lactam antibiotics:-
1) Enzymatic inhibition: plasmid mediated   e.g., β-lactamase
2) Membrane impermeability - both chromosome and plasmid 
mediated
3) Alteration of target protein e.g., Penicillin binding protein.
The β- Lactamases:-
This is a heterogeneous group of penicillin recognizing proteins. They are 
members of a super family of active site serine proteases. They act by 
cleaving an amide bond of beta lactam ring to form an acyl-enzyme 
complex. Any β-lactam antibiotic may be inactivated by these enzymes.
There are about > 170 enzymes of this kind.38 
Classification of beta lactamases  :-  
1. Early classification scheme was developed by Richmond and Sykes 
based on substrate profile and the location of genes encoding the β-
lactamases.
2. Modern  scheme  based  on  molecular  structure  was  proposed  by 
Ambler.
Most important is class A which is serine proteases that have either 
preference for penicillin or) broad spectrum activities.
They are  found either  on  chromosomes  (or)  plasmids  and are 
easily transferable from one bacteria to another.
They may be produced constitutively and may be induced.  In 
this group are the staphylococcus and some Gram negative bacilli.
Class C:  Primarily cephalosporinases, either constitutive (or) inducible.
Found on chromosomes of Gram Negative Bacilli.
Class B & D are less important.
CLASSIFICATION OF β-LACTAMASES
Class Examples Location Bacteria
Gram positive β- lactamases
Enterococcal 
Staphylococca
l
Streptococcal 
Serological types 
A-D
Plasmids
Plasmid
Plasmid
Staphylococcus aureus, 
Staphylococcus epidermidis
Enterococcus faecalis
Streptococcus uberis
Gram Negative β- Lactamase 
Class A TEM-1&2 Plasmid; broad 
spectrum 
Enterobacteriaceae, 
N.gonorrhoea, H.influenzae, 
V. cholerae
SHV – 1 Plasmid; Broad 
spectrum
Enterobacteriaceae, also 
found in chromosomes of 
Klebsiella pneumoniae.
OXA-1 Plasmid; 
oxacillinases
Escherichia coli
PSE-1 Plasmid; 
carbenicillinase in 
pseudomonas
Enterobacteriaceae, most 
common type in 
Pseudomonas aeruginosa.
BRO – 1 Plasmid; 
carbenicillinase 
base
Branhamella, moraxella
Class B Cephalosporinase Bacillus cereus
Class C Broad spectrum Chromosome Klebsiella pneumoniae, 
Proteus vulgaris, Klebsiella 
oxytoca, K. aerogenes K-1
Cephalosporinase Chromosome Escherichia coli, Bacteroides 
fragilis
Inducible Chromosome Enterobacter aerogenes, 
E.cloacae, Providencia 
rettgeri,     Pseudomonas. 
aeruginosa, 
Serratia marcescens, 
Acinetobacter baumannii
Carbapenamase
(Imipenem) 
Chromosome Xanthomonas maltophilia,
 B. fragilis, 
Serratia marcescens, 
Enterobacter cloacae.
Class D Oxacillinase - -
Recent  Classification  of  β-lactamases  is  by  Bush-Jacoby  –  Medeiros 
scheme according to substrate profile and inhibition by clavulanic acid.38 
The Bush Jacoby – Medeiros functional classification scheme 
for β-lactamames
Group Enzyme Type Inhibition 
by 
Clavulanat
e
Mole-
cular 
Class
No. of 
Enzymes
Example
1 Cephalosporinase No C 53 E.cloacae P99,M
2a Penicillinase Yes A 20 Staphylococcus 
aureus, 
Staphylococcus 
albus.
2b Broad spectrum Yes A 16 TEM-1, SHV-1
2be Extended spectrum Yes A 38 TEM-3, SHV-2, K.
2br Inhibitor resistant Diminished A 9 TEM-30,
TRC-1
2c Carbenicillinase Yes A 15 PSE-1, CARB-3, BR
2d Cloxacillinase Yes D or A 18 OXA-1, PSE-2, Str. 
Cacaoi
2e Cephalosporinase Yes A 19 Proteus vulgaris, B. 
fragilis Cep. A
2f Carbapenemase Yes A 3 E.cloacae 
IMI-1 N
3 Metalloenzyme No B 15 Xanthomonas 
maltophilia LI
4 Penicillinase N 7 Pseudomonas 
cepacia.
Some β-lactamases like that produced by Staphylococcus aureus 
are stable over several decades.  These enzymes have a rather narrow 
spectrum of activity aiming at penicillin molecule.
The  broad  spectrum,  plasmid  mediated  β-lactamases  of  Gram 
negative bacilli (GNB) such as TEM-1 and SHV-1 were stable for many 
years.
From 1980, a series of enzymatic variants appeared that had a 
broadened spectrum of activity against the newly developed β-lactam 
antibiotics.  These ESBLs were first found in Europe most commonly in 
Klebsiella species, less commonly in Escherichia coli. The number of 
enzymes continues to increase.
The new enzymes TEM-1 and SHV-1 are located on plasmids. 
But  they  might  have  been  derived  originally  from  a  chromosomal 
enzyme.  Many of the new β-lactamases differ from each other only in 
single  aminoacid  substitution  but  the  changes  have  profound 
implications for clinical management of infectious diseases.
Key Dates Showing Emergence of Β-Lactamases
Year Enzyme Organism Place
1944 Penicillinase Staphylococcus 
aureus
-
1963 TEM-1 Escherichia coli Athens
1974 SHV-1 Escherichia coli Switzerland
1978 OXA-10 Pseudomonas. 
aeruginosa
-
1982 SME-1 Serratia 
marcescens
London
1984 IMI-1 E. cloacae California
1988 Metallo 
β-lactamase
Pseudomonas 
aeruginosa
Japan
1989 Inhibitor  – 
resistant 
Penicillinase
Escherichia coli, 
Klebsiella 
pneumoniae 
France, Spain
1990 NMcA E. cloacae Paris
1991 OXA-11
OXA-14
Pseudomonas 
aeruginosa
Turkey
1991 PER-1 Pseudomonas 
aeruginosa,
Salmonella 
typhimurium
Turkey
1992 MEN-1 Escherichia coli, 
K. pneumoniae
France
1994 TOHO-1 Escherichia coli Japan
1996 PER-2 Escherichia coli, 
K. pneumoniae, 
S. typhimurium, 
P. mirabilis
Germany
1997 VEB-1 Escherichia coli Germany
Detection of β-lactamases  36  
Detection  of  β-lactamases  was  done  by  biochemical  tests  for  the 
enzymes. This was by measuring penicilloic acids which was produced 
when β-lactamases  hydrolyse  benzyl  penicillins.  The  acid  production 
was detected by 
1. Measuring  the  change  in  pH  of  an  indicator  dye  (acidometric 
method)
2. By exploiting  the  ability  of  penicilloic  acid  to  reduce  iodine  and 
reverse the formation of the blue colour when iodine complexes with 
starch. (Iodometric method)
3. Chromogenic cephalosporin method – usually nitrocephin was used. 
Nitrocephin was normally yellow but when the β-lactam ring was 
hydrolysed it turns red. 
β -lactamase inhibitors :  16  
These compounds resemble β-lactam antibiotics. They can bind 
to  β-lactam antibiotics  either  reversibly  or  irreversibly  protecting  the 
antibiotics from destruction. They serve as suicide bombers utilizing all 
available enzymes. These compounds have weak antibacterial activity 
but  are  potent  inhibitors  of  many  plasmid-encoded  and  some 
chromosomal β-lactamases. 
Three important β-lactamase inhibitors are:
1) Clavulanic acid
2) Sulbactam
3) Tazobactam
Clavulanic acid show only low level of antibacterial action but 
when combined with β-lactam antibiotics inhibition of bacteria which 
are otherwise resistant to β-lactam antibiotics was noted.
Sulbactam has broader spectrum of inhibition but less potent.
Tazobactam is as potent as clavulanic acid
EXTENDED SPECTRUM BETA LACTAMASES :
Definition: 
Enzymes  capable  of  hydrolyzing major  β  –  lactam antibiotics 
including  third  generation  cephalosporins  are  called  as  extended 
spectrum beta lactamases.
CHARACTERISTICS OF ESBLs: 16
1) They are mostly class- A cephalosporinases carried on plasmids
2) They  are  more  common  in  Klebsiella  species  followed  by 
Escherichia coli
3) Described first in Germany and France.
4) All enzymes active against   Cephalothin.
5) Imipenem and Cefoxitin not hydrolysed.
6) Comparative activity against Cefotaxime and Ceftazidine varies 
with enzymes.
7) Some enzymes active against Astreonam.
8) Resistance may not be detected by standard susceptibility tests.
9) Inhibition  of  activity  by  β-lactamase  inhibitors  can  be 
demonstrated.
Majority of ESBLs contain a serine at the active site and belong 
to Ambler’s Molecule.   Class A enzymes are characterized by an active 
site  serine,  a  molecular  mass  of  29,000  Dalton  and  hydrolysis  of 
penicillin.
ESBLs  contain  a  number  of  mutations  that  allow  them  to 
hydrolyse ESBL antibiotics. While TEM and SHV type ESBLs retain 
their  ability  to  hydrolyse  penicillin,  but  they  are  not  catalytically  as 
efficient as the parent enzymes.
ESBLs  are  not  active  against  cephamycin  and  most  strains 
expressing ESBLs are susceptible to Cefoxitin and Cefotetan.  But it has 
been  reported  that  ESBL  producing  strains  can  become  resistant  to 
cephamycin due to the loss of an outer membrane porin protein.
Major risk factors for ESBL production  
1) Prolonged stay in ICU
2) Long term use of antibiotics
3) Nursing home residency
4) Severe illness
5) High  rate  use  of  ceftazidime  and  other  Third  Generation 
Cephalosporins 
6) Use of lifelines and catheters
Types of ESBLs:-
Most ESBLs are derivatives of TEM & SHV. Now > 90 TEM 
type and > 25 SHV types are there. A few point mutations at selected 
loci with in the gene give rise to the extended spectrum phenotype.
TEM & SHV type ESBLs are most often found in Escherichia 
coli  and  Klebsiella.  pneumoniae  but  also  found  in  Proteus  species, 
Providentia species and other genera of Enterobacteriaceae.
TEM:-
TEM-2  was  the  1st  derivative  of  TEM  which  had  a  single 
aminoacid  substitution  from  the  original  β-lactamase.   This  did  not 
change the substrate profile. TEM-3 reported in 1989 was the first TEM 
type β-lactamase that displayed the ESBL phenotype.
Aminoacid residues important for ESBL production are
Glutamate →  Lysine at position 104
Arginine → Serine (or) histidine at position 164
Glycine  → Serine at Position 238
Glutamate → Lysine at position 240
TEM  type  is  often  found  in  Escherichia  coli  and  Klebsiella. 
Pneumoniae, but also reported in other members of Enterobacteriaceae 
and some other gram negative bacilli.
TEM- 42 β-lactamase was found in p. aeruginosa
TEM-17  β-lactamase  reported  in  a  blood  culture  isolate  of 
Capnocytophaga ochracia.
Characteristics of TEM-type  β-lactamases
PI Enzyme type
Broad 
spectrum
ESBL Inhibitor Resistant
5.2 TEM-12, TEM-55, 
TEM-57, TEM-58
TEM-30, TEM-31, 
TEM-35, TEM-36, 
TEM-37, TEM-38, 
TEM-41, TEM-45, 
TEM-51, TEM-73, 
TEM-74
5.3 TEM-25
5.4 TEM-1 TEM-7, TEM-19, 
TEM-20, TEM-65
TEM-32, TEM-33, 
TEM-34, TEM-39, 
TEM-40, TEM-44
5.42 TEM-29
5.55 TEM-5, TEM-17
5.59 TEM-9
5.6 TEM-2 TEM-10, TEM-11, 
TEM-13, TEM-26, 
TEM-63,  TEM-50
TEM-50,  TEM-59
5.7 TEM-68 TEM-68
5.8 TEM-42
5.9 TEM-4, TEM-6, TEM-8, 
TEM-27, TEM-72 
6.0 TEM-15, TEM-47, 
TEM-48, TEM-49, 
TEM-52, TEM-66, 
TEM-92 
6.1 TEM-28, TEM-43 
6.3 TEM-3, TEM-16, 
TEM-21, TEM-22 
6.4 TEM-56, TEM-60 
6.5 TEM-24, TEM-46, 
TEM-61 
Not 
determined
TEM-14, TEM-53, 
TEM-54 
TEM-76, TEM-77, 
TEM-78, TEM-79, 
TEM-81, TEM-82, 
TEM-83, TEM-84
SHV :-
SHV β- lactamases are most commonly found in K. pneumoniae 
and responsible for plasmid mediated resistance.
There  are  only  few derivatives  of  SHV-1  most  of  them have 
substitution of serine for glycine at position 238. Lysine for glutamate at 
position 240.
Serine residues responsible for efficient hydrolysis of ceftazidime 
and lysine residue critical for the efficient hydrolysis of cefotaxime. 
Characteristics of SHV-type -lactamases
pI Enzyme type
Broad spectrum ESBL Inhibitor resistant
7.0 OHIO-1, LEN-1 SHV-3, SHV-14
7.5 SHV-24
7.6 SHV-1, SHV-11 SHV-2, SHV-2a, SHV-6, 
SHV-8, SHV-13, SHV-19, 
SHV-20,SHV-21, SHV-22
7.8 SHV-4, SHV-7, SHV-18 
8.2 SHV-5, SHV-9, SHV-12 SHV-10
CTX-M :-
CTX  M  are  plasmid  mediated  ESBLS  which  preferentially 
hydrolyse cefotaxime.
Found mainly in salmonella.  enterica serovar typhimurium and 
Escherichia coli. But also found in other enterobacteriaceae.
It  is  suggested that  it  has  originated from Amp-C β-lactamase 
enzymes, which are chromosomal mediated.
Major types are → CTX M1, CTX-M3
CTx-M2 Type includes CTX-M2, CTX-M4
CTx-M5,  CTX  M-6,  CTX  M-7,  and  Toho-1,  Toho-2,  and 
CTX M-8.
CTX-M types hydrolyse cefotaxime than ceftazidime.
Serine residue at position 237 plays an important role in their ESBL 
activity.
Another  unique  feature  is  that  they  are  better  inhibited  by  
β-lactamase inhibitor tazobactam than by sulbactam and clavulanate.
Mostly expressed by salmonella.enterica serovar  typhi
Characteristics of CTX-M-type ESBLs
β -
Lactamase
Alternative 
name
pI Country of 
origin
Bacterial species
CTX-M-1 MEN-1 8.9 Germany, Italy E. coli
CTX-M-2 7.9 Argentina S. enterica
CTX-M-3 8.4 Poland C. freundii, E. coli
CTX-M-4 8.4 Russia S. enterica
CTX-M-5 CTX-M-3 8.8 Latvia S. enterica
CTX-M-6 8.4 Greece S. enterica
CTX-M-7 CTX-M-5 8.4 Greece S. enterica
CTX-M-8 7.6 Brazil P. mirabilis,  
E. cloacae,  
E. aerogenes,  
C. amalonaticus
CTX-M-9 8.0 Spain E. coli
CTX-M-10 8.1 Spain E. coli
Toho-1 7.8 Japan E. coli
Toho-2 7.7 Japan E. coli
OXA
Belongs  to  Class  d  and  functional  group  2d.  Characteristics 
feature  is  that  they  are  able  to  hydrolyse  ampicilin,  cephalosporin, 
cloxacillin, oxacillin and are poorly inhibited by clavulanic acid.
OXA-type ESBLs are found mainly in pseudomonas aeruginosa.
Characteristics of OXA-type ESBLs
β -
lactamase
Derivation pI Amino acid 
substitutions
vs. OXA-10
Country 
of origin
Bacterial 
species
OXA-11 OXA-10 6.4 Asn143Ser, 
Gly157Asp 
Turkey Pseudomonas 
aeruginosa 
OXA-13 OXA-10 8.0 Ile10Thr, 
Gly20Ser, 
Asp55N, 
Asn73Ser, 
Thr107Ser, 
Tyr174Phe, 
Glu229Gly, 
Ser245Asn, 
Glu259Ala 
France Pseudomonas 
aeruginosa 
OXA-14 OXA-10 6.2 Gly157Asp Turkey Pseudomonas 
aeruginosa 
OXA-15 OXA-2 8.7, 
8.9 dou
blet 
NA Turkey Pseudomonas 
aeruginosa 
OXA-16 OXA-10 6.2 Ala124Thr, 
Gly157Asp 
Turkey Pseudomonas 
aeruginosa 
OXA-17 OXA-10 6.1 Asn73Ser Turkey Pseudomonas 
aeruginosa 
OXA-18 OXA-9, 
OXA-12 
5.5 NA France Pseudomonas 
aeruginosa 
OXA-19 OXA-10 7.6 Ile10Thr, 
Gly20Ser, 
Asp55Asn, 
Thr107Ser, 
Gly157Asp,Tyr17
4Phe, 
Glu229Gly,Ser24
5Asn,Glu259Ala 
France Pseudomonas 
aeruginosa 
OXA-28 OXA-10 7.6 Ile10Thr, ly20Ser, 
Thr107Ser, 
Trp154Gly, 
Gly157Asp,Tyr17
4Phe, 
Glu229Gly,Ser24
5Asn, Glu259Ala 
France Pseudomonas 
aeruginosa 
OTHER ESBLs:-
1) PER-1 β-lactamase 18f isolated from Pseudomonas aeruginosa in 
Turkey.
2) PER-2 found in Salmonella. enterica from Argentina.
3) VEB-1 1st found in E-coli isolate from Vietnam.
4) CME-1
5) TLA-1 identified in Escherichia coli isolate from Mexico
6) SFO-1  cannot hydrolyse cephamycin and inhibited by clavulanic 
acid.
7) GES-1 resembles carbenicillinase
Characteristics of novel, unrelated ESBLs
β -
Lactamase
Closest 
relative
pI Preferred 
substrate
Country 
of origin
Bacterial species
BES-1 Penicllinase 
from Yersinia 
enterocolitica
7.5 CTX, 
CAZ, ATM
Brazil Serratia 
marcescens
FEC-1 8.2 CTX Japan Escherichia  coli
GES-1 Penicillinase 
from 
P. mirabilis
5.8 CAZ French 
Guiana
Klebsiella 
pneumoniae
CME-1 VEB-1 >9.0 CAZ Isolated 
from 
reference 
strain
Chryseobacterium 
meningosepticum
PER-1 PER-2 5.4 CAZ France Pseudomonas 
aeruginosa
PER-2 PER-1 5.4 CAZ Argentina S. enterica serovar 
Typhimurium
SFO-1 AmpA from 
S. fonticola
7.3 CTX Japan E. cloacae
TLA-1 CME-1 9.0 CAZ, 
CTX, ATM
Mexico Escherichia coli
VEB-1 PER-1,
PER-2
5.35 CAZ, ATM Vietnam/ 
Thailand
Escherichia coli
DETECTION METHODS
1) Double-disk approximation test of Tarlier et al: 
Organism was swabbed onto a Muller – Hinton agar plate. An 
antibiotic  disk  containing  one  of  the  oxyimino  β-lactam  antibiotics 
placed 30mm (centre to centre) from the amoxicillin – clavulanic acid 
disk.  Enhancement  of  zone  of  inhibition  of  the  oxyimino  β-lactam 
caused by synergy of  clavulanate  present  in  Amoxy-clav  disk  was a 
positive  result.  This  test  is  more  reliable.  Sensitivity  is  increased  by 
reducing  the  distance  between  the  disks  to  20mm.  Addition  of 
clavulanate (4µg/ml) to the MHA increases the sensitivity.
Disc strength: - 3rd generation cephalosporins 30µg/ disc,
Coamoxyclav - 20µg amoxicillin + 10µg clavulanic acid.36 
Ceftazidime is the best sentinel antibiotic for suspecting resistance to 3rd 
generation cephaloporins.16 
2) Three Dimensional Test:
Advantage  is  simultaneous  determination  of  antibiotic 
susceptibility and β-lactamase substrate profile.
2 types of inoculam are prepared.
1) Inoculum-1: contains 109 – 1010 CFU/ml of active ESBL producers.
2)Inoculum-2: Contains 0.5 Mc Farland Std. (150 million organisms/ml)
Plate  was  inoculated  as  for  disc  diffusion  procedure  with 
inoculam-2. A circular slit was cut on the agar 4mm inside the position 
at  which  the  antibiotic  discs  was  placed  and  109-1010 inoculum was 
poured into it.  Distortion or discontinuity in the circular inhibition zone 
is interpreted as positive for ESBL production.
3) Inhibitor Potentiated Disc Diffusion Test :
Cephalosporin  disc  is  placed  on  clavulanate  containing  and 
without clavulanate MHA plates. More than 10mm increase in the zone 
of inhibition of the clavulanate containing MHA plate indicates ESBL 
production.
Disk Approximation test : Cefoxitin (inducer) disc in placed at a 
distance  of  2.5cm  from  cephalosporin  disc,  production  of  inducible 
β-lactamase was indicated by flattening of  the  zone of inhibition of 
cephalosporin  disk  towards  inducer  disk  by  > 1mm indicates  ESBL 
production.
4) MIC Reduction test: 
An  eight  fold  reduction  in  the  MIC  of  3rd generation 
cephalosporins in the presence of clavulanic acid indicates production of 
ESBL.
5) Vitek ESBL test :
Four  wells  containing  cards  are  inoculated.  A  predetermined 
reduction in  growth of  cephalosporin well  containing clavulanic  acid 
compared  with  level  of  growth  in  well  with  cephalosporin  alone 
indicates the presence of ESBL.
6) E-test :
E test ESBL strips have 2 gradients, on one end ceftazidime and 
on the opposite end ceftazidime plus clavulanic acid.  MIC is the point 
of intersection of the inhibition ellipse with the E-test strip edge.
Ratio of ceftazidime MIC and ceftazidime clavulanic acid MIC > 
8 indicates presence of ESBLs.
7) Phenotypic Confirmation Test
Antibiotic susceptibility testing done on Miller Hinton Agar with 
0.5 Mc Farland’s standard of the organism.38 
Lawn  culture  of  the  organism  was  made  and  3rd generation 
cephalosporin, Ceftazidime (30µg) disc was tested alone and along with 
their combination for 10mg of clavulanic acid.  Organisms with 5mm 
increase  in  zone  of  inhibition  for  ceftazidime  /  clavulanic  acid 
(30µg/10µg) are confirmed as ESBLs.
(NCCLS  recommends  MIC  > 2µg/ml  for  cefotaxime, 
ceftazidime, astreonam, ceftriaxone (or) cefpodoxime as potential ESBL 
producers).
2 indicators of ESBLs are 
i) 8 fold reduction in MIC when 3 GC are used with clavulanic acid.
ii)  >  5mm  increase  in  diameter  of  inhibition  zone  when  using  disc 
diffusion method with 3rd generation cephalosporin and clavulanic acid 
combined disc.
8) Molecular detection methods: 
Tests already described only presumptively identify the presence 
of ESBL.
Earlier,  determination  of  isoelectric  point  was  sufficient  for 
studying ESBL, But nowadays since there are >90 TEM type and >25 
SHV type of β-lactamase and many of them have same isoelectric point, 
it has become impossible to detect the individual ESBLs. 
So  detection  of  β-lactamases  using  DNA  probes  that  were 
specific for SHV was used but they were labour intensive.
Easiest and most reliable molecular method used to detect ESBLs 
is PCR with oligonucleotide primers that are specific for a β-lactamase 
gene Oligonucleotide primers can be chosen from sequence available in 
Gen  Bank.  Primers  are  usually  chosen  to  anneal  to  regions  where 
various point mutation are known to occur.
MEDICAL SIGNIFICANCE OF DETECTION OF ESBL
Patients  having  infections  caused  by  ESBL  –  producing 
organisms  are  at  increased  risk  of  treatment  failure  with  expanded 
spectrum β-lactam antibiotics. So it is recommended that if an organism 
was confirmed to produce ESBL it is considered as resistant to all 3rd 
Generation cephalosporins.
Many ESBL isolates will  not be phenotypically resistant;  even 
through  their  MIC  is  so  high.  ESBL  producing  strains  have  been 
established in many hospitals producing epidemic diseases especially in 
Intensive Care Units.16 Failure to control outbreaks has resulted in new 
mutant types in some institution.
Problems in detection:-
1) Variable affinity of ESBLs for different substrate.
2) Inoculum  effect:  -  MIC  for  3rd generation  cephalosporins 
increases if the inoculum is 107 CFU instead of 105 CFU.  So we must 
be very careful.
TREATMENT:-
Carbapenems are most effective and reliable as they are highly 
resistant  to  the  hydrolytic  activity  of  all  ESBLs  due  to  the 
Trans 6 – hydroxy ethyl group.
Meropenem is the most active drug with MIC lower than that of 
Imipenem.59
Few β - lactam, 7α-  methoxy cephalosporins such as Cefoxitin, 
cefotetan and latamoxcef are effective. Alternatively, fluoroquinolones 
and  amino  glycosides  may  be  used  if  they  show in  vitro  activity,30 
although  clinical  data  for  their  use  are  absent,  a  Beta  lactam-Beta 
lactamase  inhibitor  combination  such  as  amoxicillin-clavulanate  or 
Piperacillin Tazobactam may also be a further option to consider. All 
these agents should be used with caution, as their susceptibility varies 
among ESBL producers. Cephamycin, such as Cefoxitin and cefotetan, 
although  active  in  vitro  are  not  recommended  for  treating  such 
infections, because of the relative ease with which these strains decrease 
the expression of outer membrane proteins, rendering them resistant30 
In urinary tract infection combination with clavulanic acid can be 
used.
PREVENTION AND CONTROL MEASURES:-
Proper  infection  control  practices  and  barrier  methods  are 
essential  to  prevent  spreading  and  outbreaks  of  ESBL  producing 
bacteria. The reservoir for these bacteria seems to be the gastrointestinal 
tract  of  patients.  Alternative  reservoirs  could  be  the  oropharynx, 
colonised wounds, and urine. The contaminated hands and stethoscopes 
of  healthcare  providers  are  important  factors  in  spreading  infection 
between  patients.  Essential  infection  control  practices  should  include 
hand washing by hospital personnel, increased barrier precautions, and 
isolation of patients colonized or infected with ESBL producers. Other 
practices  that  have  minimized  the  spread  of  such  organisms  include 
clinical and bacteriological surveillance of patients admitted to intensive 
care  units  and  antibiotic  cycling,  as  well  as  policies  of  restriction, 
especially on the empirical use of broad spectrum antimicrobial agents 
such as the third and fourth generation cephalosporins and imipenem 
AIM AND OBJECTIVES OF THE STUDY
 To find  the  incidence  of  ESBL producing organisms in  Intensive 
care units of Government Stanley Hospital. 
  To prove association between prolonged stay in intensive care units 
and production of ESBL.
 To assess the outcome of treatment in patients with infections due to 
ESBL producing bacteria.
 To  formulate  treatment  policy  for  those  patients  who  are  having 
severe  infection  resistant  to  treatment  with  routine  antibiotics  for 
avoiding further emergence of Extended Spectrum  β- Lactamases
MATERIALS AND METHODS
This  study  was  a  ‘descriptive  study’  done  among  patients  in 
Intensive  Care  Units  from  December  2004  to  February,  2006  at 
Government Stanley Hospital, Chennai. 
A total of 100 patients from both sexes in age group between 20 
to 60 years admitted in Intensive Care Units and having infection for 
more than a week were included in the study. Isolates obtained from 
various clinical samples like blood, urine, pus, sputum, tracheobronchial 
aspirates, drainage tube tips taken from Intensive medical and intensive 
surgical care units were included in the study.
 Inclusion criteria:
Presence of obvious prolonged infections not responding to treatment with 
routine drugs used in intensive care units, like ciprofloxacin, Gentamycin, 
Amikacin and Cefotaxim.
METHODOLOGY:- 
Methodology includes  
1. Collection of samples
2. Identification of the organisms
3. Selection of resistant strains
4. Detection of ESBL production
5. Identification of SHV, CTX-M-3 and CTX-M-14 genes
SPECIMEN COLLECTION   :9,16 
Urine – Clean-catch midstream urine was collected in non-catheterized 
patients 
In case of indwelling catheter, tubing was clamped off above the 
port to allow collection of freshly voided urine.  The catheter port or 
wall of the tubing was then cleaned vigorously with 70 % ethanol, and 
urine was aspirated via a needle and syringe; the integrity of the closed 
drainage  system  was  maintained  to  prevent  the  introduction  of  
micro-organisms into the bladder.
Blood - Venipuncture site was cleaned with betadine and 70% alcohol. 
Blood  was  drawn  at  time  of  febrile  episodes.  5  ml  of  blood  was 
collected in 50 ml of Brain Heart Infusion broth to give a dilution of one 
in ten and incubated at 37o C.
Wound  Swab   :  Wound  area  was  wiped  with  sterile  saline  or  70% 
alcohol. Swab was rolled along leading edge of the wound.
Endotracheal Aspirate collected in a sterile container under a septic 
precaution.
Drainage Tube Tips - Collected in a sterile container
 IDENTIFICATION OF THE ORGANISM   :- 
Organisms  were  identified  by  colony  morphology  Gram’s 
staining and biochemical reactions such as oxidase test,  catalase test, 
indole  test,  citrate  utilisation  test,  triple  sugar  iron  (TSI)  test, 
carbohydrate fermentation tests, oxidation- fermentation (OF) test and 
motility  after  inoculating  them  on  routine  media  used  in  our 
microbiology  laboratory  namely  nutrient  agar,  blood  agar  and 
Macconkey’s agar.  Main isolates included Escherichia coli, Klebsiella 
pneumoniae,  Klebsiella  oxytoca,  Proteus  mirabilis,  Proteus  vulgaris, 
Pseudomonas aeruginosa, and few other species.                     .  
Differentiating Characters of some isolates commonly producing ESBL
Organism TSI
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Escherichia coli A/A Not 
utilised + - + + + + + + +
Klebsiella 
Pneumonia
A/A utilised - - + + + + + + -
Klebsiella 
oxytoca
A/A utilised + - + + + + + + -
Proteus.
species
A/A  with 
H2S + + - + + - + - - +
Pseudomonas 
.aeruginosa
K/No 
change utilised + + + - - - + - +
Acinetobacter 
baumannii
K/No 
Change
 Not 
utilised - - + - - - - - -
Note:   A/A = Acid slant / Acid butt,   +   = Positive,    - =   Negative   
SELECTION OF  RESISTANT STRAINS
Routine  disc  diffusion  susceptibility  testing  of  the  strains  was 
performed by modified Kirby Bauer Method46 in Mueller-Hinton agar 
medium. 
Storage of Antimicrobial Disks 
The container was refrigerated at 4 – 8o C or kept frozen    at 
minus 14o C.   β-  Lactam antibiotics were stored frozen.  Some labile 
agents like imipenem and clavulanic acid retained greater stability when 
stored frozen until the day of use. 
Disk container was removed from refrigerator one or two hours 
before use and brought to room temperature.
Once  a  cartridge  of  disks  has  been  removed  from  its  sealed 
package, it was placed in a tightly sealed, desiccated container.
Turbidity Standard for Inoculam Preparation
To standardize the inoculam density for a susceptibility test,  a 
BaSO4 turbidity standard equivalent to a 0.5 McFarland standard was 
used. 
 
Preparation of Inoculum :
Tip  of  3-5  representative  colonies  were  picked  up  and  put  in 
4-5ml of broth and incubated at 37oC for 2 – 6 hrs to attain 0.5 Mc 
Farland’s  standard  which  corresponds  to  150  million  organisms/ml. 
If  it  was  more  turbid  then  some  more  broth  was  added  and 
adjusted to 0.5 Mc Farland’s standard by comparing against a card with 
white background and contrasting black lines.
Inoculation of MHA Plates:
Within  15  minutes  of  adjusting  the  turbidity  of  the  inoculum 
suspension,  a  sterile  cotton swab was dipped into it.   The swab was 
rotated several times and pressed firmly on the inside wall of the tube 
above the fluid level to remove excess broth from the swab.
Dried  surface  of  Muller  Hinton  agar  plate  was  inoculated  by 
streaking the swab over the entire sterile agar surface. This procedure 
was  repeated  by  streaking  two  more  times  rotating  the  plate 
approximately 60o each time to ensure an even distribution of inoculum. 
As a final step, the rim of the agar was swabbed.
The lid  was let  ajar  for  3  to  5 minutes  but  not  more than 15 
minutes  to  allow any excess  surface  moisture  to  be  absorbed before 
applying drug impregnated discs.
Application of discs to Inoculated agar plates  . 
The predetermined battery of antimicrobial discs which included 
Co-trimoxazole,  Amoxycillin,  Gentamycin,  Amikacin,  Ciprofloxacin, 
Cefotaxime, Ceftazidime, Ceftriaxone and meropenem were dispensed 
on agar plates and pressed down to ensure completes contact with the 
agar surface. Discs were distributed evenly so that they were not closer 
than 24mm from centre to centre.  Not more than 5 discs for a 100mm 
plate.46 Because some of  the drug diffuses almost instantaneously,  ‘a 
disc  was  not  relocated  once  it  has  come  into  contact  with  the  agar 
surface. Instead, a new disc was placed in another location on the agar’. 
Plates were inverted and incubated at 37oC for 16-18 hrs.
Reading plates and interpretation of results :
After 16-18 hrs of incubation each plate was examined.  If the 
plate  was  satisfactorily  streaked,  and  the  inoculum  was  correct,  the 
resulting zones of inhibition will be uniformly circular and there will be 
a confluent lawn of growth. If individual colonies were apparent, then 
the inoculum was too light and the test was repeated.  The diameter of 
the zones of complete inhibition was measured, including the diameter 
of the disc. Zones were measured to the nearest whole millimeter using 
a ruler which was held on the back of the inverted Petri plate. 
The  Petri  plate  was  held  a  few  inches  above  a  black,  non 
reflecting background and illuminated with reflected light.
The zone margin was taken as area showing no obvious, visible 
growth that can be detected with the unaided eye. Faint growth of tiny 
colonies, which could be detected only with a magnifying lens at the 
edge of the zone of inhibited growth, was ignored. However, discrete 
colonies growing within a clear zone of inhibition was sub-cultured,  
re-identified and retested.
The sizes of the zones of inhibition were interpreted by referring 
to the NCCLS standards and reported as susceptible,  intermediate,  or 
resistant to the agents that have been tested.
Controls used  with each batch:-
1. Escherichia coli                ATCC 25922
2. Pseudomonas aeruginosa ATCC 27853
3. Staphylococcus aureus     ATCC 25923 
ZONE SIZE INTERPRETATIVE CHART IN ACCORDING TO 
NCCLS Kirby-Bauer Chart
Sl. 
No.
Drug Disk 
Content
mcg
Resistant
mm or
less
Intermediat
e
mm
Sensitive
mm or
more
1 Amoxycillin 10 mcg 14 mm 15-16 mm 17 mm
2 Co-trimoxazole 1.25+3.75 10 11-15 16
3 Cephalexin 30 14 15-17 18
4 Norfloxacin 10 12 13-16 17
5 Ciprofloxacin 5 15 16-20 21
6 Gentamycin 10 12 13-14 15
7 Cefotaxime 30 14 15-22 23
8 Ceftriaxone 30 13 14-20 21
9 Ceftazidime 30 14 15-17 18
10 Amikacin 30 14 15-16 17
11 Amoxycillin  – Clavulanic acid 20/10 19 - 20
12. Meropenem 10µg < 13 14-15 > 16
ESBL DETECTION
Isolates found to be resistant (or) with decreased susceptibility to 
cefotaxime and ceftazidime were tested for the presence of ESBLs.
1) Double disc synergy test :
To  demonstrate  a  synergistic  action  between  a  3rd generation 
cephalosporin and clavulanic acid.
Isolates  were  grown  to  0.5  Mc  Farland’s  standard  and  lawn 
culture of it was made on a Muller Hinton agar plate. 
Discs  of  3rd generation  cephalosporin  cefotaxime  (30µg)  and 
ceftazidime (30µg) were placed 20mm apart from an amoxicillin (20µg) 
and  clavulanic  acid  (10µg)  combined  disc  (augmentin)  centre  to 
centre.10 Incubated at  37oC for 16-18 hrs.  Organisms were said to be 
ESBL producing.
If inhibition around the 3rd generation cephalosporins showed a 
clear extension towards augmentin disc.
If  neither  disc  were  inhibitory  alone  but  bacterial  grown  was 
inhibited between the 2 discs.
2)MIC determination : Done by agar dilution method.
Preparation of media: Muller Hinton agar was prepared in tubes 
and autoclaved.  It is then allowed to cool in a 50oC water bath.
Serial  dilution  of  the  3 GCs ceftazidime and cefotaxime were 
prepared in sterile distilled water to give a final concentration ranging 
from 2μg – 2048μg/ml of agar.
After adding the drugs to the medium at 50o C it was mixed well 
and poured into sterile petridishes. (The media was used immediately 
otherwise potency of drugs will be affected.  We can inoculate upto 12 
different organisms in a single plate).
A control plate containing the test medium without the antibiotic 
was prepared for each series of test.
Inoculum Preparation: 
At least  3-5 well  isolated colonies  of  the  same morphological 
type were selected from an agar culture plate. Top of each colony was 
touched  with  a  loop  and  the  growth  was  transferred  into  a  tube 
containing 4-5ml of  broth.   The broth culture was incubated at  37oC 
until it reaches 0.5 Mc Farland’s standard (usually 2-6 hrs). This result 
in growth corresponding to 150 million organisms/ml.
Inoculation of test plates: 
Plates  of  various  concentrations  were  divided  into  required 
number (9-12 divisions / plate) 0.003 ml of inoculum was put into the 
appropriate quadrant and incubated at 37oC for 16-20 hrs.
Minimum inhibitory concentration was the lowest concentration at 
which no visible growth occurs.
Isolates  were  tested  for  various  concentrations  of  cephalosporin 
combined with 2µ g/ml of clavulanic acid from 0.5µ g to 2048µ g / ml of 
agar and the MIC determined.
Quality Control used for ESBL detection : 
Klebsiella pneumoniae ATCC 700603 [as positive control]
Escherichia coli ATCC 25922 as negative control.
IDENTIFICATION OF SHV, CTX-M-3 AND CTX-M-14 GENES
1.  DNA EXTRACTION was  done  by  alcohol  extraction  method  from 
young broth culture of the organisms.
2 .POLYMERASE CHAIN REACTION 
PCR was carried out in a Peltier Thermal cycler (PTC 200) MJ 
Research PCR which had  
Inital denaturation for about 5 minutes at 94 oC.  Each cycle had a 
2nd denaturation for about 1 minute.
Annealing at 58 o C for 1 minute.
Thirty five cycles were performed and a final extension was done 
for 10 minutes at 72 o C
3. GEL DOCUMENTATION: 
After the reaction, 25 µl. of the amplified samples were run on a 
1.5 % agarose gel and electrophoresis done at 50 V with 1 x Tris Accetate 
EDTA buffer.  Amplicons were visualised using Ethidium bromide 
staining and scored using 100 bp DNA ladder as reference.
Gels were viewed in a U - V gel documentation Unit and Photographed.
RESULTS
Bacterial isolates obtained from One hundred patients admitted in 
various  intensive  care  units  of  Government  Stanley  Hospital  were 
studied during a period of   about 1 year from     December, 2004 to 
February,  2006  to  find  the  incidence  of  Extended  Spectrum  Beta 
Lactamases  (ESBL)  producing  gram  negative  bacilli  among  them. 
Study included patients of both sexes between 20 to 60 years of age. 
Specimen included were Urine, Blood, Trachebronchial aspirate, wound 
swab and drainage tube tips.
Out of one hundred and fifteen specimens collected, one hundred 
and ten organisms were isolated. Ninety five isolates of gram negative 
bacilli  were  identified  as  Escherichia  coli,  Klebsiella  pneumoniae, 
Klebsiella  oxytoca,  Proteus  mirabilis,  Proteus  vulgaris,  Pseudomonas 
aeruginosa  and  Acinetobacter  baumannii  by  biochemical  reactions. 
Fifteen out of them were found to be gram positive cocci.
The Results were analysed as follows.
Table 1
Age And Sex Distribution Of Cases (   n = 100 ) 
Total numbers of cases taken for study were 100, which included total of 
58 male (58 %) and 42 female (42 %). Among them between 
20-30 years of age there were 11 male and 8 female, between 31-40 years 
15 male and 7 female, between 41-50 years there were 17 male and 11 
female and between 51-60 years there were 15 male and 16 female. 
Table – 2 A
Isolates obtained from various specimens
From intensive care units (n=115)
Total Culture positives Culture negatives
115 110 (95.65 %) 5 (4.35 %)
Out of the 115 specimens obtained, 110 were found to be culture 
positive and 5 were culture negative
Table – 2 B
Organisms Isolated from Culture Positive Samples (n = 110)
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Urine 50 22 10 2 6 4 3 1 0 2
Blood 16 2 6 0 0 0 0 1 6 1
Tracheo 
bronchial 
Aspirate
11 2 4 2 0 1 0 0 1 1
Wound 
Swab
16 3 2 0 3 0 5 0 2 1
Drainage 
Tube 
Tips
17 7 2 1 3 0 3 0 0 1
Total 110 36 
(32.7%)
24
(21.8%)
5
(4.5%)
12
(10.9%)
5
(4.5%)
11
(10.0%)
2
(1.8%)
9
(8.2%)
6
(5.5%)
Out of 110 isolates 36 (32.7%) were Escherichia coli, 24 (21.8%) 
were  Klebsiella  pneumoniae,  5  (4.5%)  were  Klebsiella oxytoca 12 
(10.9%)  were  proteus  mirabilis,  5  (4.5%)  were  proteus  vulgaris,  11 
(10%)  were  pseudomonas  aeruginosa 2  (1.8%)  were  Acinetobacter, 
9(8.2%)  were  Staphylococcus  aureus  and  6  (5.5%)  were  Coagulase 
negative Staphylococcus.
Table –3 A
Resistant Strains Among GNB
Number of Isolates Resistant to 3rd generation 
cephalosporins 
95 49
Table –3 B
ESBL Positive Isolates Among Gram Negative Bacilli   (n=95) 
Methods DDST MIC Meropenem 
sensitivity 
Positive Isolates 37 (38.95%) 37 (38.95%) 37 (38.95%)
Out of ninety five gram negative bacilli 37 (38.95%) were found 
to be ESBL producers by Double disc synergy test and MIC test. All the 
37 were sensitive to Meropenem. 
Table – 4
ESBL Producing Gram Nagative Organisms
Obtained from various specimens (n=95)
Specimen
Total 
Isol
ate
s
ESBL 
Producer
s
Percentage
Urine 48 19 39.58%
Blood 9 3 33.33%
TBA 9 4 44.44%
Wound Swab 13 5 38.46%
DTT 16 6 37.50%
Total 95 37 38.95%
Out  of  95  gram  negative  bacilli  37  (38.95  %)  were  ESBL 
producers.  Out  of  48  urinary  isolates  19  (39.58%)  were  ESBL 
producers. .From blood total numbers of isolates were 9, out of which 3 
(33.33%) were ESBL producers. Out of 9 isolates from Trachebronchial 
aspirate  4(44.44%)  were  ESBL producers.  Total  numbers  of  isolates 
from wound swab were 13, out of which 5(38.46%) were found to be 
ESBL producers. Out of 16 isolates from drainage tube tips 6(37.50%) 
were ESBL producers.
Table – 5
ESBL Among Gram Negative Bacilli
From various specimens  (n=95)
Organism Total ESBL Percentage
Escherichia.coli 36 16 44.44%
Klebsiella 
pneumoniae
24 11 45.83%
Klebsiella oxytoca 5 2 40.00%
Proteus mirabilis 12 3 25.00%
Proteus vulgaris 5 1 20.00%
Pseudomonas 
aeruginosa
11 4 27.27%
Acinetobacter 
baumannii
2 0 0.00 %
TOTAL 95 37 38.95%
Out  of  36  Escherichia.coli  isolates  16  (44.44%)  were  ESBL 
producers.  From  24  Klebsiella  pneumoniae  isolates  11(45.83%) 
were ESBL producers.  2 (40%) Out of 5 Klebsiella oxytoca isolates 
were ESBL producers. Out of 12 Proteus mirabilis isolates 3 (25%) 
were ESBL producers. Out of 5 Proteus vulgaris isolates 1 (20%) 
was an ESBL producer.  From 11 Pseudomonas aeruginosa isolates 
4 (27.27%) were ESBL producers. Acinetobacter baumannii isolates 
were 2, but they were not ESBL producer. 
Table – 6
ESBL Producing Organisms among Urine Isolates
(n=48)
Out of 48 isolates of gram negative bacilli  19 (39.58 %) were 
ESBL producers.  Out  of  22  Escherichia.coli  isolates  10  (45.45  %) 
were  ESBL  producers.   Out  of  10  Klebsiella  pneumoniae  isolates 
5(50%) were ESBL producers.  Out of 2 Klebsiella oxytoca isolates 1 
(50%)  was  ESBL  producer.  From  6  Proteus  mirabilis  isolates  1 
(16.67%) was  ESBL producer.   Out  of  4  Proteus  vulgaris  isolates  1 
(25%)  was  an  ESBL  producer.   From  3  Pseudomonas  aeruginosa 
isolates 1 (33.33%) was ESBL producer. Acinetobacter  baumannii 
isolates was 1, but it was not an ESBL producer.
Table – 7
ESBL Producers among Blood Isolates (n=9)
Isolates Total
ESBL 
PRODUC
ERS
Percentage
Escherichia.coli 2 1 50.00%
Klebsiella pneumoniae 6 2 33.33%
Klebsiella oxytoca 0 0 0
Proteus mirabilis 0 0 0
Proteus vulgaris 0 0 0
Pseudomonas aeruginosa 0 0 0
Acinetobacter 1 0 0
Total 9 3 33.33 %
Out of 9 gram negative bacilli 3 (33.33 %) were ESBL producer. 
Out of 2 Escherichia.coli isolates 1 (50 %) was ESBL producer. Out of 6 
Klebsiella  pneumoniae  isolates  2(33.33%)  were  ESBL  producers. 
Acinetobacter  baumannii  isolate  was  1,  but  it  was  not  an  ESBL 
producer.
Table – 8
ESBL Producing Organisms from
Tracheobronchial Aspirate (TBA) (n=9)
Isolates Total
ESBL 
Produ
cers
Percentage
Escherichia.coli 2 1 50.00%
Klebsiella pneumoniae 4 2 50.00%
Klebsiella oxytoca 2 1 50.00%
Proteus mirabilis - - -
Proteus vulgaris 1 - -
Pseudomonas aeruginosa - - -
Total 9 4 44.44 %
Out of 9 isolates of gram negative bacilli 4 (44.44 %) were ESBL 
producers.  Out  of  2  Escherichia.coli  isolates  1  (50  %)  was  ESBL 
producer. Out of 4 Klebsiella pneumoniae isolates 2(50%) were ESBL 
producers.   Out  of  2 Klebsiella  oxytoca isolates 1 (50%) was ESBL 
producer. 
Table – 9
ESBL Producing Organisms Isolated From Wound Swab 
(n=13)
Out  of  13 isolates  of  gram negative  bacilli  5  (38.46  %)  were 
ESBL producers.  Out of 3 Escherichia.coli isolates 1 (33.33 %) were 
ESBL producers. 1(50%) out of 2 Klebsiella pneumoniae isolates was 
ESBL producer.   Out of 3 Proteus mirabilis  isolates 1 (33.33%) was 
ESBL producer.  Out of 5 Pseudomonas aeruginosa isolates 2 (40 %) 
were ESBL producers.
Table – 10
ESBL Producing Organisms Isolated 
From Drainage Tube Tips (n=16)
Isolates Total
ESBL 
Produ
cers
Percentage
Escherichia.coli 7 3 42.86 %
Klebsiella pneumoniae 2 1 50.00 %
Klebsiella oxytoca 1 - -
Proteus mirabilis 3 1 33.33 %
Proteus vulgaris - - -
Pseudomonas aeruginosa 3 1 33.33 %
Total 16 6 37.50 %
Out of 16 isolates of gram negative bacilli 6 (37.50 %) were ESBL 
producers. From 7 Escherichia.coli isolates 3 (42.86 %) were ESBL 
producers.  1(50%)  out  of  2  Klebsiella  pneumoniae  isolates  was 
ESBL producer.  Out of 3 Proteus mirabilis isolates 1 (33.33%) was 
ESBL  producer.   Out  of  3  Pseudomonas  aeruginosa  isolates  1 
(33.33%) was ESBL producer.
Table – 11
MIC of  Cefotaxime For  ESBL Producing Organisms (n = 37)
Minimum inhibitory concentration of Cefotaxime for the ESBL 
producing organisms in the study was between 64 µg/ml of agar 
to  2048 µg/ml of agar 
Table – 12
MIC OF  CEFOTAXIME FOR  ESBL PRODUCING 
ORGANISMS
IN PRESENCE OF 2 µg/ml OF CLAVULANIC ACID (n = 37)
Isolates Total Concentration of Cefotaxime in µg/ml of Agar0.5 1 2 4 8 16 32 64 128 256 512
Escherichia.coli 16 1 1 10 14 16 16 16 16 16 16 16
Klebsiella 
pneumonia
e
11 2 3 9 10 10 10 10 11 11 11 11
Klebsiella 
oxytoca
2 - 2 2 2 2 2 2 2 2 2 2
Proteus 
mirabilis
3 - 1 2 3 3 3 3 3 3 3 3
Proteus vulgaris 1 - - - 1 1 1 1 1 1 1 1
Pseudomonas 
aeruginosa
4 - - 2 4 4 4 4 4 4 4 4
Minimum inhibitory concentration of Cefotaxime for the ESBL 
producing organisms in the study was between 0.5 µg/ml of agar to 64 
µg/ml of agar in the presence of clavulanic acid at a concentration of 2 
µg/ml of agar showing 8 fold reductions in MIC.
Table – 13
MIC of Ceftazidime For  ESBL Producing Organisms (n =37)
Isolates
Tota
l
Concentration of ceftazidime in µg/ml of agar
2 4 8 16 32 64 128 256 512 1024 2048
Escherichia.coli 16 - - - - - 2 5 12 14 16 16
Klebsiella 
pneumonia
e
11 - - - - - 1 2 3 6 10 11
Klebsiella 
oxytoca
2 - - - - - 1 2 2 2 2 2
Proteus 
mirabilis
3 - - - - - - 1 2 2 3 3
Proteus vulgaris 1 - - - - - - - - 1 1 1
Pseudomonas 
aeruginosa
4 - - - - - - 1 1 2 4 4
Minimum inhibitory concentration of Ceftazidime for the ESBL 
producing organisms in the study was between 64 µg/ml of agar 
to  2048 µg/ml of agar 
Table – 14
MIC of Ceftazidime for  ESBL Producing Organisms 
in presence of 2 µ g/ml    of Clavulanic acid (n = 37) 
Isolates Total Concentration of Ceftazidime in µg/ml of agar0.5 1 2 4 8 16 32 64 128 256 512
Escherichia.coli 16 1 12 14 16 16 16 16 16 16 16 16
Klebsiella 
pneumonia
e
11 2 4 11 11 11 11 11 11 11 11 11
Klebsiella 
oxytoca
2 2 2 2 2 2 2 2 2 2 2 2
Proteus 
mirabilis
3 1 3 3 3 3 3 3 3 3 3 3
Proteus vulgaris 1 - - 1 1 1 1 1 1 1 1 1
Pseudomonas 
aeruginosa
4 - 2 4 4 4 4 4 4 4 4 4
Minimum inhibitory concentration of Ceftazidime for the ESBL producing 
organisms in the study was between 0.5 µg/ml of agar to 4 µg/ml of agar in the presence of 
clavulanic acid at a concentration of 2 µg/ml of agar showing 8 fold reductions in MIC
Table – 15
Gene Identification by Polymerase Chain Reaction (n = 37)
Isolates Total SHV CTX-M3 CTX-M14
Escherichia.coli 16 - 9 2
Klebsiella pneumoniae 11 11 2 -
Klebsiella oxytoca 2 1 1 -
Proteus mirabilis 3 - - -
Proteus vulgaris 1 - - -
Pseudomonas aeruginosa 4 - - -
PCR for determination of SHV, CTX-M-3, and CTX-M-14 
identified. SHV gene in all the Klebsiella pneumoniae and one 
Klebsiella oxytoca isolates, CTX-M-3 was found in 9 Escherichia.coli, 2 
Klebsiella pneumoniae and one Klebsiella oxytoca isolates. CTX-M-14 
was found in 2 Escherichia.coli isolates.  2 Klebsiella pneumoniae and 
one Klebsiella oxytoca isolates showed both SHV and CTX-M-3.
Table – 16
Antibiotic Susceptibility of ESBL producing and non ESBL 
producing GNB To Various non – β –Lactam Antibiotics (n = 95)
Antibiotics
Resistant Strains   
n = 49 Sensitive 
Strains 
n=46
ESBL Producers
n = 37
Non ESBL 
Producer
s   n= 12
Ampicillin - - 15 (32.60%)
Amoxycillin - - 20 (43.48%)
Co-trimoxazole 5 (13.51%) - 28 (60.87%)
Gentamycin - - 23 (50.00%)
Amikacin 18 (48.65%) 5 (41.67%) 46 (100 %)
Ciprofloxacin 9 (24.32%) 3 (25.00%) 46 (100 %)
Out of 37 ESBL producers, 5 (13.51%) were sensitive to Co-trimoxazole, 18 
(48.65%) were sensitive to Amikacin and 9 (24.32%) were sensitive to Ciprofloxacin.
DISCUSSION
Emergence  of  ESBL  due  to  the  extensive  use  of  extended 
spectrum Cephalosporins  since  1980s  were  a  significant  evolution in 
antimicrobial resistance.
ESBLs are now a problem in hospitalised patients throughout the 
world. Incidence among clinical isolates vary greatly world wide and in 
Geographic areas and are rapidly changing overtime. Only few studies 
have  been  conducted  to  find  the  incidence  and  prevalence  of  ESBL 
producers in Indian hospitals but ESBL producing Gram negative bacilli 
may have evolved in several hospitals all over the country. Since the 
incidence  from ICU was  found to  be  high  from various  studies,  the 
present study was conducted to find the incidence of ESBL producing 
Gram negative  bacilli  from ICU of  Stanley  medical  college  hospital 
from  Urine,  Blood,  Tracheobronchial  aspirate,  wound  swab  and 
drainage tube tips.
Double  Disc  Synergy  Test  (DDST)  being  a  simple  and  cost 
effective procedure was taken as the method of choice for screening of 
ESBL producing organisms in this study.
100 cases of both male and female between 20-60 years of age 
were included in this study which gives a ratio of 1: 0.72. (58/42)
Among the 115 specimen obtained 110 organisms were isolated 
and 95 out of them were Gram negative bacilli.
Among  the  95  Gram  negative  bacilli  49  were  resistant  to  3 rd 
Generation cephalosporins (51.58 %) and 37 out of them were positive 
by DDST for ESBL (38.95 %) Correlating with study of Shukla et al55 
(30.18%), Baby Padmini53 (40 %), Sumeeta  et al56 (30.2%) and Ashwin 
et al8 (33.3%).
In  the  present  study ESBLs from urine was  39.58% which is 
correlating with study by Baby Padmini53 (40%).  45.45% (10/12) of 
Escherichia.coli  isolated  from urine  were  ESBL producers,  which  is 
correlating with study by Bithika Duttaroy10 (46.5%)
ESBLs among Klebsiella pneumoniae from urine was 50% in the 
present study, which is correlated with the study of Bithika10 (58%) and 
Baby Padmini53 (40%).
In the present study ESBL producing Klebsiella oxytoca from all 
specimen was40% (2/5) and from urine it was 50% (1/2). In a study by 
Christopher et al15 from Virginia in 1997 it was 4.4%. This difference 
may be due to change in Geographical area and change in period of 
study.
In the present study total  ESBL of proteus mirabilis  was 25% 
(3/12)  and  from  urine  it  was  16.67%  (1/6).  From  the  study  of 
C.Rodrigues et al12 it was 33.33% (1/3). This disparity may be due to the 
less number of isolates in their study than the present study.
Total  ESBL among Proteus  vulgaris  in  the  present  study  was 
20% (1/5) which is correlating with the study of C. Rodrigues et al12 and 
from  urine  it  was  25%(1/4)  This  also  correlated  with  the   study  of 
C.Rodrigues et al 12
Total ESBL among Pseudomonas aeruginosa in the present study 
was 36.36% (4/11) but in the study by C. Rodrigues et al12 it was only 
5.9% (4/68). This disparity may be due to extensive use of 3rd generation 
cephalosporins in the Intensive Care Units of Stanley Medical College 
Hospital
Number  of  ESBLs  producing  Pseudomonas  aeruginosa  from 
urine was 33.33% (1/3) which was high when compared to study by 
Rodrigues et al12 which may be due to increased use of third generation 
cephalosporins and problem with urinary catheterisation.
In  the  present  study  only  2  isolates  were  Acinetobacter 
baumannii, among which one from urine and another one from blood. 
One  from  urine  was  found  to  be  resistant  to  third  generation 
cephalosporin  but  not  found  to  be  an  ESBL  producer.  One 
Acinetobacter baumannii isolated from blood was found to be sensitive 
to  3rd  generation  cephalosporin.  This  correlated  with  the  study  of 
Rodgrigues et al in which number of ESBL among 16 Acinetobacter 
baumannii isolates was none but they have proved the association of 
depressed mutants’ with ESBLs is 33.3% (5/16)
From blood in the present study there were totally 33.33% ESBL 
producing organisms (3/9) but from a study by Bithika et al10 it  was 
11.32% (6/53) and in a study from Belgium by Eddy vercauteran et al19 
in 1997 it was 5.8% (5/86). The increase of ESBL in the present study 
may be due to the prolonged stay of the patients in the Intensive care 
units in our study.
From blood,  in the present study ESBL producing Escherichia 
coli was 50 %( 1/2). But in the study by Bithika et al10 from Baroda it 
was 18.18% (6/33). This difference may be because of the number of 
isolates
From  blood,  in  the  present  study  ESBL  producing  Klebsiella 
pneumoniae  was  33.33%  (2/16)  which  correlated  with  study  by 
Vercauteran et al19 from Belgium
In  the  present  study  ESBL  producing  organisms  from 
Tracheobronchial aspirate was 44.44% (4/9). In a study by A. Subha1 
from Chennai there were no ESBL from the respiratory specimen. This 
may be due to the low number of isolates tested by them, or may be due 
to the difference in age group studied or may be due to the increased use 
of third generation cephalosporin in our Intensive Care Units.
In the present study ESBL producing Escherichia coli, Klebsiella 
pneumoniae  and  Klebsiella  oxytoca  from  Tracheobronchial  aspirate 
were 50%(1/2),  50% (2/4) and 50%(1/2) in which Klebsiella oxytoca 
equals  Escherichia  coli  and  Klebsiella  pneumoniae  which  correlates 
with the study of Christopher et al15 from Virginia in 1997.
In  the  present  study  ESBLs  from  wound  swab  was  30.77%  
(4/13). This correlated with the study by Shukla et al55 36.1%, study by 
Bithika et al10 30.18% (16/54) and study from JIPMER by Ashwin et al8 
22.14% (11/49)
In  the  present  study  ESBL  producing  Escherichia  coli  from 
wound swab was 33.33 %( 1/3). This varies from the study of Ashwin 
et al8from JIPMER in 2000 was 58.06 %( 18/31). This may be due to the 
low number of isolates in the present study.
ESBL producing Klebsiella pneumoniae from wound swab in the 
present study was 50.00 %( 1/2) which correlated with study by Ashwin 
et al8 was 43.75% (7/16) and Shukla et al55 was 36.1%
ESBL producing Proteus mirabilis from wound swab in the 
present study was 33.33% (1/3).
ESBL producing Pseudomonas aeruginosa in the present study 
was 40% (2/5)  from wound swab which correlates with the study of 
Ashwin et al 8 (15 %.)
ESBL  producing  organisms  from  various  other  specimen  like 
catheter tips wound drainage tube tips and endotracheal tube tips was 
37.5%(6/16)  constituting  Escherichia  coli  42.86%  (3/7),  Klebsiella 
pneumoniae 50% (1/2),  Proteus mirabilis 33.33% (1/3),  Pseudomonas 
aeruginosa 33.33% (1/3). This correlated with the study of Christopher 
et al15 from Virginia29.41% (5/17)
Minimum inhibitory concentration for Cefotaxime by agar dilution method 
for the 37 ESBL producing organisms varied from 64 µg/ml to 2048 µg/ml. 
This showed MIC 50s at 256 µg/ml and MIC 90s at 1024 µg/ml for 
Escherichia coli. MIC 50s at 512 µg/ml and MIC 90s at 1024 µg/ml for 
Klebsiella pneumoniae.
MIC 50s at 64µg/ml and MIC 90s at 256 µg/ml for Klebsiella 
oxytoca.
 MIC 50s  was  512  µg/ml  and  MIC 90s  was  1024  µg/ml  for 
Proteus mirabilis.
ESBL producing Proteus vulgaris and Pseudomonas aeruginosa 
were inhibited at 1024 µg/ml.
When cefotaxime was combined with 2 µg/ml. of clavulanic acid 
the MIC was reduced to 0.5 µg/ml -  8 µg/ml,  except one organisms 
which showed MIC  of  64 µg/ml.
MIC for ceftazidime was between 64 µg/ml - 2048 µg/ml, with 
MIC  50s  for  Escherichia  coli,  Klebsiella  pneumoniae,  Klebsiella 
oxytoca, Proteus mirabilis and Pseudomonas aeruginosa as 256 µg/ml, 
512 µg/ml, 64 µg/ml, 256 µg/ml respectively. 
MIC was reduced to 0.5 µg/ml - 8 µg/ml of ceftazidime, when 
combined with 2 µg/ml of clavulanic acid. From a study by Bithika et 
al10 from Baroda MIC for third generation cephalosporins was between 
2- 1024 µg/ml and it was reduced to 0.25-128 µg/ml when clavulanic 
acid  was  added at  a  concentration  of  2  µg/ml.  So  the  present  study 
correlates well with the study of Bithika et al.
Polymerase  Chain  Reaction  for  identification  of  SHV, 
CTX – M-3 and CTX-M-14 showed presence of SHV genes in all the 
Klebsiella  pneumoniae and one  Klebsiella  oxytoca  isolate,  CTX-M-3 
was  identified  in  9  Escherichia  coli,  2  Klebsiella  pneumoniae  and 1 
Klebsiella oxytoca isolate. CTX-M-14 was identified in 2 Escherichia 
coli isolates. 
This  correlates  with  the  study  of  Ju-Hsin  Chia  et  al31 from 
Taiwan, where most of the Escherichia coli isolates showed CTX-M-3 
and Klebsiella pneumoniae isolates showed SHV.
SHV, CTX-M-3, CTX-M-14 genes were not identified in Proteus 
mirabilis and Pseudomonas aeruginosa; this may be due to presence of 
some  other  genes  like  OXA  responsible  for  resistance  in  these 
organisms.
In the present study the ESBL producing organisms  found to be 
sensitive to co-trimoxazole  were 13.51% (5/37), sensitive to amikacin 
were  48.65%  (18/37),  sensitive  to  ciprofloxacin  were 
16.22%(6/37).which correlated with a study by S. Baby padmini53 from 
Coimbatore in which the sensitivity were 26%, 89%,9% respectively for 
co-trimoxazole, amikacin and ciprofloxacin.
All  the  ESBLs  were  sensitive  to  meropenem  (100%)  which 
correlated with the study by Shukla et al55 from Haryana.
SUMMARY
Hundred cases with prolonged infection (more than a week) from 
Intensive care units of Government Stanley Hospital, Chennai, between 
“December 2004 to February 2006” formed the study group.
Specimens like urine,  blood,  Tracheobronchial  aspirate,  wound 
swabs,  catheter  tips  and  endotracheal  tube  tips  were  cultured  and 
organisms were identified by Gram’s staining and various biochemical 
reactions. 
Antibiotic  susceptibility  testing  was  done  including  third 
generation cephalosporins and the gram negative bacilli which included 
Escherichia coli , Klebsiella pneumoniae , Klebsiella oxytoca ,Proteus 
mirabilis , proteus vulgaris , Pseudomonas aeruginosa and Acinetobacter 
baumannii found to be resistant to third generation cephalosporin were 
screened for ESBL production by Double disc synergy test (DDST) .
Total of 37 out of 95 Gram negative bacilli (38.95%) were found 
to  be  ESBL  producers  .  presence  of  ESBL  among  urine  ,  blood  , 
Tracheobronchial  aspirate  ,wound  swabs  were   39.58%,33.33%, 
44.44%, 37.5%  and 38.46 % respectively.
Among the Gram negative bacilli  presence of  ESBL was high 
among Klebsiella  pneumoniae (45.33%) followed by Escherichia coli 
(44.44%).
 MIC for the isolates was between 64- 2048 µg/ml of agar for 
cefotaxime and ceftazidime which was reduced to 0.5 - 64 µg/ml and 
0.5- 4 µg/ml of agar respectively in the presence of 2 µg/ml of agar. 
All  the  37  organisms  (100%)  were  found  to  be  sensitive  to 
meropenem  which  is  expensive.  Some  of  the  ESBL  producing 
organisms  were  sensitive  to  cheaper  drugs  like  Co-trimoxazole 
(13.51%), Amikacin (48.65%) and to Ciprofloxacin (16.22%).
By Polymerase Chain Reaction SHV gene was identified in all 
the  Klebsiella  pneumoniae,  and  CTX-M-3  identified  in  most  of  the 
Escherichia coli isolates.
CONCLUSION
Isolation  of  ESBL  producing  organisms  from  Intensive  Care 
Units of Govt. Stanley Medical College Hospital was 38.95% by DDST 
and MIC which was high when compared to other studies from south 
India.  Isolation  of  ESBL  producing  organisms  were  more  in 
tracheobronchial  aspirate  of  patients  put  on  ventilator  (44.44%) 
followed by urine (39.46%) and wound swab (38.46%).  
1.  In  Intensive  care  units  widespread  use  of  third  generation 
Cephalosporins  has  been  cited  as  a  contributing  factor  in  the 
development of ESBL mediated resistance along with prolonged stay 
and intubations.  So by following proper  infection control  and giving 
correct  antibiotics  after  proper  screening  ESBL  production  can  be 
minimised 
2.  DDST being simple  and cheaper  should be included in the 
microbiology laboratories as a routine test for early deduction of ESBL 
producing organisms in specimen from critically ill patients.
3.  Though  meropenem  was  100%  sensitive,  ESBL  producing 
organisms were  also  sensitive  to  cheaper  drugs  like,  Co-trimoxazole 
(13.51%), Amikacin (48.65%) and Ciprofloxacin (16.22%). Hence if we 
screen carefully we can minimise the cost of treatment for the patients 
with infections due to ESBL producing organisms.
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